Clinical Trials Logo

Clinical Trial Summary

This study will develop and pilot a smartphone intervention, LiveWell, to enhance patient self-management of bipolar disorder and facilitate more efficient, timely care delivery by mental health providers. The intervention uses a mobile application to collect daily self-report and continuous behavioral data and adapts intervention content to create a highly tailored and user-responsive treatment system. Patient data collected by the phone will also be provided to clinicians to allow for better evaluation and targeting of treatment. The goal is to reduce symptoms and prevent relapse in patients with bipolar disorder.


Clinical Trial Description

Bipolar disorder is a severe and chronic mental illness that significantly increases mortality and greatly impairs functioning. Despite the use of pharmacological treatments, multiple acute episodes, long episode duration, and significant inter-episode sub-syndromal symptoms are common in patients with bipolar disorder. As a result, patients with bipolar disorder are symptomatically ill about half the time. There is clear evidence that the addition of psychotherapeutic interventions to medication management improves treatment outcomes, yet only about half of bipolar patients receive combined treatment. Current therapies also have limitations in terms of: 1) reliance on subjective patient self report and 2) difficulties in identifying warning signs of impending episodes. Furthermore, direct measurement of observable daily patterns of behavior is not routinely available, even though alterations in sleep and activity are core symptoms of bipolar disorder. Improving access to and long-term engagement in psychosocial interventions is needed to substantially improve treatment.

The investigators are developing a smartphone intervention that aims to make proven psychosocial interventions for bipolar disorder more readily and routinely accessible to patients as part of their day-to-day lives. The intervention, called LiveWell, will capture and feedback data about sleep and activity to assist patients in regularizing daily rhythms as well as help them monitor, recognize, and manage early warning signs of impending mood episodes. Behavioral and self-report data collected by the phone will also be used to provide clinicians with information regarding patient clinical status. This will increase patient-provider communication and allow for better evaluation and targeting of treatment.

Participation in the study will last 4 months. All participants will first undergo initial assessments that will include a telephone interview and a face-to-face interview with a certified study psychiatrist for the purpose of confirming diagnosis. Eligible participants will then be assigned randomly to the LiveWell or TAU group. Participants assigned to either group will be provided with a smartphone and wrist-worn device, and will be asked to carry the phones with them whenever they leave home and to wear the wrist-worn devices 24-hours a day 7 days a week. Participants assigned to the LiveWell intervention will be asked to undergo a 16 week psychosocial intervention consisting of phone-based self-monitoring and educational tools to help them learn skills to better manage symptoms. Participants assigned to the TAU group will be asked to provide limited self-report data on wellness and sleep. All participants, regardless of assigned group, will be asked to participate in assessments delivered over the phone to assess presence and severity of mood symptoms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02405117
Study type Interventional
Source Northwestern University
Contact
Status Completed
Phase N/A
Start date January 10, 2014
Completion date April 10, 2017

See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study